Mohamad NV

ORCID: 0000-0002-6254-5132 · 2 papers in corpus
review 2021
Endocrine, metabolic & immune disorders drug targets ·doi:10.2174/1871530321666201216164410

Prolonged treatment with Gonadotropin-Releasing Hormone (GnRH) agonists is known to induce bone loss among prostate cancer patients. However, evidence on the skeletal effects of GnRH antagonists is relatively less well-known. This review ai…

2018
International journal of medical sciences ·doi:10.7150/ijms.22732

Introduction: Orchidectomy is currently the preferred method to induce bone loss in preclinical male osteoporosis model. Gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer treatment can induce testosterone deficiency but…